• A Hemostatic Powder for Upper Gastrointestinal Bleeding...

    Added On : 6th June 2013

    A Hemostatic Powder for Upper Gastrointestinal Bleeding Shows Promise

    In a small case series, a nonbiologic powder, TC-325, achieved hemostasis in all patients without any adverse events.

  • Use Ciprofloxacin with Adalimumab...

    Added On : 24th May 2013

    Use Ciprofloxacin with Adalimumab for Perianal Crohn Disease

    At least half of draining fistulas closed in 71% of patients randomized to combination therapy versus 47% with anti-TNF therapy alone.

  • ANCA Is Associated with Chronic Pouchitis

    Added On : 10th May 2013

    Patients who were positive for antineutrophil cytoplasmic antibody were more likely to develop chronic pouchitis after total proctocolectomy and ileoanal pouch anastomosis.

  • Sofosbuvir-Based Therapy for HCV Infection...

    Added On : 27th April 2013

    Sofosbuvir-Based Therapy for HCV Infection: The Results Are In

    The evidence shows superior efficacy and tolerability of sofosbuvir-based regimens versus those currently available, particularly in patients with HCV genotype 1.

  • Where Are We with Pentoxifylline...

    Added On : 14th April 2013

    Where Are We with Pentoxifylline for Severe Alcoholic Hepatitis?

    A pooled analysis of available trial data showed a 53% reduction in mortality from hepatorenal syndrome, but no reduction in overall mortality, compared with placebo.

  • Remove Small Polyps During Insertion

    Added On : 4th March 2013

    This recommendation holds up in the first randomized controlled trial of the practice.

    Removal of small polyps during colonoscopic insertion might prevent colonoscopists from being unable to find them during withdrawal. This practice is commonly advocated by experts and considered standard practice by many colonoscopists. To evaluate whether this method actually results in fewer missed polyps compared with polypectomy during withdrawal only, investigators randomized 301 patients to undergo removal of polyps <1 cm in size during both colonoscopic insertion and withdrawal or during colonoscopic withdrawal only.

  • Clopidogrel, Proton-Pump Inhibitors, and Cardiovascular Events

    Added On : 3rd March 2011

    Clopidogrel, Proton-Pump Inhibitors, and Cardiovascular Events

    A careful analysis of drug exposure after coronary stent implantation found no significant association between major cardiovascular events and concomitant use of clopidogrel and PPIs.

    Concerns about the combined use of clopidogrel and proton-pump inhibitors (PPIs) began when studies suggested that PPIs impaired the intended antiplatelet activity of clopidogrel. This effect was attributed to a competitive interaction at the cytochrome P450 pathway, which is required for the biotransformation of the prodrug clopidogrel to its active metabolite. These studies led to a rapid onslaught of retrospective observational database analyses that reported an increased likelihood of clinical adverse cardiovascular events in patients taking this drug combination. However, a fundamental problem with these retrospective analyses has been their reliance on discharge prescription data, without accounting for varying medication exposures after discharge.

  • Computerized Prediction of Mortality from...

    Added On : 16th March 2011

    Computerized Prediction of Mortality from Upper Gastrointestinal Bleeding

    An artificial neural-network program that used pre-endoscopy data was superior to the Rockall scoring system.

  • Venous Thromboembolism and Inflammatory...

    Added On : 30th March 2011

    Venous Thromboembolism and Inflammatory Bowel Disease

    Risk for VTE was two times higher in patients with IBD than in sex- and age-matched controls.

    Patients with inflammatory bowel disease (IBD) have elevated risk for venous thromboembolism (VTE) — including deep venous thrombosis (DVT) and pulmonary embolism (PE) — and possibly arterial thrombosis.

  • Low Risk for Colorectal Cancer in Patients...

    Added On : 13th April 2011

    Low Risk for Colorectal Cancer in Patients with Inflammatory Bowel Disease

    Hospital-based data from the Netherlands confirm low risk and reveal protective effects of immunosuppressive thiopurines and antitumor necrosis factor.